OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Aft on Disseminating Tumor Cells and Prognosis

June 14th 2013

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

June 13th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Dr. Hutson on Tivozanib for Renal Cell Carcinoma

June 13th 2013

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).

Dr. Saenger on Combining Targeted and Immune Agents

June 12th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Dr. Figlin on Sequencing mTOR Inhibitors and TKIs in RCC

June 12th 2013

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.

Dr. Powell Discusses CPI-613 in Hematologic Malignancies

June 11th 2013

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Van Tine on Arginine Deiminase for Sarcomas

June 11th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Dr. Goy on Lenalidomide for Mantle Cell Lymphoma

June 10th 2013

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).

Dr. Lehman Discusses the Use of Breast MRI

June 10th 2013

Constance D. Lehman, MD, PhD, Vice Chair, Radiology Department, University of Washington School of Medicine, Medical Director, Imaging, Seattle Cancer Care Alliance, discusses the use of breast MRI.

Dr. Andtbacka Reviews the Efficacy of T-VEC in Melanoma

June 7th 2013

Robert Andtbacka, MD, from the Huntsman Cancer Institute, provides an overview of the phase III OPTiM trial that explored treatment with talimogene laherparepvecin patients with advanced melanoma.

Dr. Rutgers Compares ART or ALND in Breast Cancer

June 7th 2013

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Dr. Finn on the Future of Palbociclib in Breast Cancer

June 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Dr. Churpek on Gene Mutations in Breast Cancer

June 6th 2013

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

Dr. Shastri on Vinegar as a Cervical Cancer Screening Tool

June 6th 2013

Surendra Srinivas Shastri, MD, Professor, Preventive Oncology, Tata Memorial Hospital, Mumbai, India, discusses the results of a study looking at vinegar (acetic acid) as a cervical cancer screening tool.

Dr. Shaw Describes LDK378 in ALK-Positive Lung Cancer

June 5th 2013

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.

Dr. Herbst on the Emergence of Immunotherapy in Cancer

June 5th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.

Penny Daugherty Discusses Patient Support

May 31st 2013

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, discusses how she supports a patient who has received a cancer diagnosis.

Dr. Gomella Discusses the PSA Screening Debate in 2013

May 31st 2013

Leonard G. Gomella, MD, chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

Dr. Piccart on the Success of Trastuzumab

May 30th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the success of trastuzumab for the treatment of breast cancer.

Dr. Cooperberg on the Impact of Prostate Cancer Screening

May 29th 2013

Matthew Cooperberg, MD, MPH, from the UCSF Helen Diller Family Comprehensive Cancer Center, describes the future and historical impact of screening in prostate cancer.